The ERBB network: At last, cancer therapy meets systems biology

Nature Reviews Cancer

Volumn 12, Issue 8, 2012, Pages 553-563

  Yarden, Yosef ^a   Pines, Gur ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CETUXIMAB; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; IMMUNOGLOBULIN M; K RAS PROTEIN; LAPATINIB; NERVE GROWTH FACTOR; NEU DIFFERENTIATION FACTOR; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CLINICAL RESEARCH; COLORECTAL CANCER; DRUG EFFICACY; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTRADUCTAL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MENETRIER DISEASE; MOLECULAR CLONING; NERVE CELL GROWTH; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN MOTIF; REVIEW; SYSTEMS BIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DRUG DISCOVERY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; ONCOGENE PROTEINS V-ERBB; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 84864367360     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3309     Document Type: Review

References (182)

1. Avraham, R. & Yarden, Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nature Rev. Mol. Cell Biol. 12, 104-117 (2011).
2. Hynes, N. E. & MacDonald, G. ErbB receptors and signaling pathways in cancer. Curr. Opin. Cell Biol. 21, 177-184 (2009).
3. Baselga, J. & Swain, S. M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Rev. Cancer 9, 463-475 (2009).
4. Cohen, S. & Levi-Montalcini, R. Purification and properties of a nerve growth-promoting factor isolated from mouse sarcoma 180. Cancer Res. 17, 15-20 (1957).
5. Savage, C. R. Jr, Inagami, T. & Cohen, S. The primary structure of epidermal growth factor. J. Biol. Chem. 247, 7612-7621 (1972).
6. Cohen, S. & Carpenter, G. Human epidermal growth factor: isolation and chemical and biological properties. Proc. Natl Acad. Sci. USA 72, 1317-1321 (1975).
7. Scher, C. D. & Todaro, G. J. Selective growth of human neoplastic cells in medium lacking serum growth factor. Exp. Cell Res. 68, 479-481 (1971).
8. Sporn, M. B. & Todaro, G. J. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med. 303, 878-880 (1980).
9. Todaro, G. J., De Larco, J. E. & Cohen, S. Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells. Nature 264, 26-31 (1976).
10. Roberts, A. B. et al. Transforming growth factors: isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc. Natl Acad. Sci. USA 77, 3494-3498 (1980). (Pubitemid 10012261)
11. Carpenter, G. & Cohen, S. 125I-labeled human epidermal growth factor. Binding, internalization, and degradation in human fibroblasts. J. Cell Biol. 71, 159-171 (1976).
12. Cohen, S., Fava, R. A. & Sawyer, S. T. Purification and characterization of epidermal growth factor receptor/protein kinase from normal mouse liver. Proc. Natl Acad. Sci. USA 79, 6237-6241 (1982). (Pubitemid 13219841)
13. Hunter, T. & Cooper, J. A. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell 24, 741-752 (1981). (Pubitemid 11071313)
14. Schreiber, A. B., Lax, I., Yarden, Y., Eshhar, Z. & Schlessinger, J. Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. Proc. Natl Acad. Sci. USA 78, 7535-7539 (1981). (Pubitemid 12186177)
15. Downward, J. et al. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307, 521-527 (1984). (Pubitemid 14135812)
16. Waterfield, M. D. et al. Platelet-derived growth factor is structurally related to the putative transforming protein p28sis of simian sarcoma virus. Nature 304, 35-39 (1983). (Pubitemid 13063102)
17. Ullrich, A. et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309, 418-425 (1984). (Pubitemid 14102443)
18. Hendler, F. J. & Ozanne, B. W. Human squamous cell lung cancers express increased epidermal growth factor receptors. J. Clin. Invest. 74, 647-651 (1984). (Pubitemid 14054014)
19. Libermann, T. A. et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313, 144-147 (1985). (Pubitemid 15192341)
20. Sugawa, N., Ekstrand, A. J., James, C. D. & Collins, V. P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl Acad. Sci. USA 87, 8602-8606 (1990).
21. Schechter, A. L. et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 312, 513-516 (1984). (Pubitemid 15182278)
22. Bargmann, C. I., Hung, M. C. & Weinberg, R. A. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45, 649-657 (1986). (Pubitemid 16063129)
23. Yamamoto, T. et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319, 230-234 (1986). (Pubitemid 16128786)
24. Kraus, M. H., Popescu, N. C., Amsbaugh, S. C. & King, C. R. Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J. 6, 605-610 (1987).
25. Schechter, A. L. et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 229, 976-978 (1985). (Pubitemid 16248489)
26. Bargmann, C. I., Hung, M. C. & Weinberg, R. A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319, 226-230 (1986). (Pubitemid 16128785)
27. Coussens, L. et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230, 1132-1139 (1985). (Pubitemid 16169997)
28. Di Fiore, P. P. et al. Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells. Cell 51, 1063-1070 (1987).
29. Di Fiore, P. P. et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237, 178-182 (1987). (Pubitemid 17095921)
30. Hudziak, R. M., Schlessinger, J. & Ullrich, A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc. Natl Acad. Sci. USA 84, 7159-7163 (1987).
31. Hung, M. C., Yan, D. H. & Zhao, X. Y. Amplification of the proto-neu oncogene facilitates oncogenic activation by a single point mutation. Proc. Natl Acad. Sci. USA 86, 2545-2548 (1989).
32. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987). (Pubitemid 17231334)
33. Slamon, D. J. et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989). (Pubitemid 19147683)
34. van de Vijver, M. J. et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med. 319, 1239-1245 (1988).
35. Lu, J. et al. 14-3-3ζ Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 16, 195-207 (2009).
36. Yarden, Y. & Weinberg, R. A. Experimental approaches to hypothetical hormones: detection of a candidate ligand of the neu protooncogene. Proc. Natl Acad. Sci. USA 86, 3179-3183 (1989). (Pubitemid 19129580)
37. Wen, D. et al. Neu differentiation factor: a transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit. Cell 69, 559-572 (1992).
38. Holmes, W. E. et al. Identification of heregulin, a specific activator of p185erbB2. Science 256, 1205-1210 (1992).
39. Peles, E. et al. Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationships. EMBO J. 12, 961-971 (1993). (Pubitemid 23095845)
40. Yarden, Y. & Schlessinger, J. The EGF receptor kinase: evidence for allosteric activation and intramolecular self-phosphorylation. Ciba Found. Symp. 116, 23-45 (1985).
41. Yarden, Y. & Schlessinger, J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 26, 1443-1451 (1987). (Pubitemid 17045875)
42. Kokai, Y. et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58, 287-292 (1989). (Pubitemid 19191411)
43. Goldman, R., Levy, R. B., Peles, E. & Yarden, Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry 29, 11024-11028 (1990).
44. Yarden, Y. & Ullrich, A. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 57, 443-478 (1988).
45. Plowman, G. D. et al. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc. Natl Acad. Sci. USA 87, 4905-4909 (1990).
46. Plowman, G. D. et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc. Natl Acad. Sci. USA 90, 1746-1750 (1993). (Pubitemid 23069933)
47. Kraus, M. H., Issing, W., Miki, T., Popescu, N. C. & Aaronson, S. A. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc. Natl Acad. Sci. USA 86, 9193-9197 (1989). (Pubitemid 20010391)
48. Knighton, D. R. et al. Structural features that specify tyrosine kinase activity deduced from homology modeling of the epidermal growth factor receptor. Proc. Natl Acad. Sci. USA 90, 5001-5005 (1993). (Pubitemid 23182963)
49. Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A. & Carraway, K. L. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc. Natl Acad. Sci. USA 91, 8132-8136 (1994).
50. Carraway, K. L. & Cantley, L. C. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78, 5-8 (1994).
51. Pinkas-Kramarski, R. et al. Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation. Oncogene 15, 2803-2815 (1997). (Pubitemid 28004569)
52. Riese, D. J., van Raaij, T. M., Plowman, G. D., Andrews, G. C. & Stern, D. F. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol. Cell. Biol. 15, 5770-5776 (1995).
53. Tzahar, E. et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16, 5276-5287 (1996). (Pubitemid 26315047)
54. Karunagaran, D. et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J. 15, 254-264 (1996). (Pubitemid 26029205)
55. Graus-Porta, D., Beerli, R. R., Daly, J. M. & Hynes, N. E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 16, 1647-1655 (1997). (Pubitemid 27151960)
56. Holbro, T. et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl Acad. Sci. USA 100, 8933-8938 (2003). (Pubitemid 36899201)
57. Sliwkowski, M. X. et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269, 14661-14665 (1994).
58. Alimandi, M. et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10, 1813-1821 (1995).
59. Wallasch, C. et al. Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J. 14, 4267-4275 (1995).
60. Meyer, D. & Birchmeier, C. Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development. Proc. Natl Acad. Sci. USA 91, 1064-1068 (1994). (Pubitemid 24048509)
61. Gassmann, M. et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor. Nature 378, 390-394 (1995).
62. Levi, A. D. et al. The influence of heregulins on human Schwann cell proliferation. J. Neurosci. 15, 1329-1340 (1995).
63. Sato, J. D. et al. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol. Biol. Med. 1, 511-529 (1983).
64. Peng, D. et al. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 56, 3666-3669 (1996). (Pubitemid 26272010)
65. Aboud-Pirak, E. et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J. Natl Cancer Inst. 80, 1605-1611 (1988). (Pubitemid 19006809)
66. Baselga, J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur. J. Cancer 37, S16-S22 (2001). (Pubitemid 32938125)
67. Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004). (Pubitemid 38944402)
68. Bonner, J. A. et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-578 (2006). (Pubitemid 43209104)
69. Fiske, W. H. et al. Efficacy of cetuximab in the treatment of Menetrier's disease. Sci. Transl. Med. 1, 8ra18 (2009).
70. Drebin, J. A., Link, V. C., Stern, D. F., Weinberg, R. A. & Greene, M. I. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 697-706 (1985).
71. Hudziak, R. M. et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9, 1165-1172 (1989). (Pubitemid 19071685)
72. Carter, P. et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA 89, 4285-4289 (1992).
73. Park, S. et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18, 160-170 (2010).
74. Stagg, J. et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108, 7142-7147 (2011).
75. Baselga, J. et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737-744 (1996).
76. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001). (Pubitemid 32222155)
77. Hortobagyi, G. N. Trastuzumab in the treatment of breast cancer. N. Engl. J. Med. 353, 1734-1736 (2005). (Pubitemid 41464714)
78. Schoeberl, B. et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res. 70, 2485-2494 (2010).
79. Umezawa, H. et al. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J. Antibiot. 39, 170-173 (1986). (Pubitemid 16174654)
80. Yaish, P., Gazit, A., Gilon, C. & Levitzki, A. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242, 933-935 (1988). (Pubitemid 19015255)
81. Fukuoka, M. et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol. 21, 2237-2246 (2003). (Pubitemid 46621858)
82. Cohen, M. H., Williams, G. A., Sridhara, R., Chen, G. & Pazdur, R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8, 303-306 (2003). (Pubitemid 36929716)
83. Thatcher, N. et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366, 1527-1537 (2005). (Pubitemid 41540110)
84. Cohen, M. H., Johnson, J. R., Chen, Y. F., Sridhara, R. & Pazdur, R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10, 461-466 (2005). (Pubitemid 41266326)
85. Miller, V. A. et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 22, 1103-1109 (2004). (Pubitemid 41095044)
86. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004). (Pubitemid 38637993)
87. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004). (Pubitemid 38720929)
88. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101, 13306-13311 (2004). (Pubitemid 39209661)
89. Sordella, R., Bell, D. W., Haber, D. A. & Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004). (Pubitemid 39100331)
90. Stephens, P. et al. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431, 525-526 (2004).
91. Prickett, T. D. et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nature Genet. 41, 1127-1132 (2009).
92. Soung, Y. H. et al. Somatic mutations of the ERBB4 kinase domain in human cancers. Int. J. Cancer 118, 1426-1429 (2006).
93. Rusnak, D. W. et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res. 61, 7196-7203 (2001). (Pubitemid 32946515)
94. Spector, N. L. et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 23, 2502-2512 (2005). (Pubitemid 47050840)
95. Geyer, C. E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006). (Pubitemid 46021510)
96. Ryan, Q. et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 13, 1114-1119 (2008).
97. Schweitzer, R. & Shilo, B. Z. A thousand and one roles for the Drosophila EGF receptor. Trends Genet. 13, 191-196 (1997). (Pubitemid 27219584)
98. Schoeberl, B., Eichler-Jonsson, C., Gilles, E. D. & Muller, G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nature Biotech. 20, 370-375 (2002). (Pubitemid 34286330)
99. Barabasi, A. L. & Albert, R. Emergence of scaling in random networks. Science 286, 509-512 (1999).
100. Kirschner, M. & Gerhart, J. Evolvability. Proc. Natl Acad. Sci. USA 95, 8420-8427 (1998). (Pubitemid 28350502)
101. Kitano, H. Systems biology: a brief overview. Science 295, 1662-1664 (2002). (Pubitemid 34202893)
102. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127-137 (2001). (Pubitemid 33674041)
103. Oda, K., Matsuoka, Y., Funahashi, A. & Kitano, H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst .Biol. 1, 2005.0010 (2005).
104. Kholodenko, B. N., Demin, O. V., Moehren, G. & Hoek, J. B. Quantification of short term signaling by the epidermal growth factor receptor. J. Biol. Chem. 274, 30169-30181 (1999).
105. Dikic, I. & Giordano, S. Negative receptor signalling. Curr. Opin. Cell Biol. 15, 128-135 (2003). (Pubitemid 36332186)
106. Freeman, M. Feedback control of intercellular signalling in development. Nature 408, 313-319 (2000).
107. Levkowitz, G. et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev. 12, 3663-3674 (1998). (Pubitemid 29019647)
108. Haj, F. G., Verveer, P. J., Squire, A., Neel, B. G. & Bastiaens, P. I. Imaging sites of receptor dephosphorylation by PTP1B on the surface of the endoplasmic reticulum. Science 295, 1708-1711 (2002). (Pubitemid 34202905)
109. Lin, S. Y. et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nature Cell Biol. 3, 802-808 (2001).
110. Ni, C. Y. Murphy, M. P., Golde, T. E. & Carpenter, G. γ-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. Science 294, 2179-2181 (2001). (Pubitemid 33150677)
111. Fiorentino, L. et al. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol. Cell. Biol. 20, 7735-7750 (2000).
112. Amit, I. et al. A module of negative feedback regulators defines growth factor signaling. Nature Genet. 39, 503-512 (2007). (Pubitemid 46514770)
113. Garrett, T. P. et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell 110, 763-773 (2002). (Pubitemid 35283965)
114. Ogiso, H. et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110, 775-787 (2002). (Pubitemid 35291060)
115. Ferguson, K. M. et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 11, 507-517 (2003). (Pubitemid 36297057)
116. Garrett, T. P. et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11, 495-505 (2003). (Pubitemid 36293841)
117. Cho, H. S. et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756-760 (2003).
118. Cho, H. S. & Leahy, D. J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297, 1330-1333 (2002). (Pubitemid 34913167)
119. Bouyain, S., Longo, P. A., Li, S., Ferguson, K. M. & Leahy, D. J. The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand. Proc. Natl Acad. Sci. USA 102, 15024-15029 (2005). (Pubitemid 41513328)
120. Greenfield, C. et al. Epidermal growth factor binding induces a conformational change in the external domain of its receptor. EMBO J. 8, 4115-4123 (1989). (Pubitemid 20066854)
121. Franklin, M. C. et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5, 317-328 (2004). (Pubitemid 38482068)
122. Zhang, X., Gureasko, J., Shen, K., Cole, P. A. & Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137-1149 (2006). (Pubitemid 43866200)
123. Jura, N., Shan, Y., Cao, X., Shaw, D. E. & Kuriyan, J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl Acad. Sci. USA 106, 21608-21613 (2009).
124. Shi, F. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl Acad. Sci. USA 107, 7692-7697 (2010).
125. Telesco, S. E., Shih, A. J., Jia, F. & Radhakrishnan, R. A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network. Mol. Biosyst. 7, 2066-2080 (2011).
126. Jura, N. et al. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 137, 1293-1307 (2009).
127. Red Brewer, M. et al. The juxtamembrane region of the EGF receptor functions as an activation domain. Mol. Cell 34, 641-651 (2009).
128. Bocharov, E. V. et al. Spatial structure of the dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state. J. Biol. Chem. 283, 6950-6956 (2008).
129. Mi, L. Z. et al. Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor. Nature Struct. Mol. Biol. 18, 984-989 (2011).
130. Amit, I., Wides, R. & Yarden, Y. Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol. Syst. Biol. 3, 151 (2007).
131. Nahta, R., Yu, D., Hung, M. C., Hortobagyi, G. N. & Esteva, F. J. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nature Clin. Pract. Oncol. 3, 269-280 (2006). (Pubitemid 43731112)
132. Benvenuti, S. et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67, 2643-2648 (2007). (Pubitemid 46548951)
133. Di Fiore, F. et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br. J. Cancer 96, 1166-1169 (2007). (Pubitemid 46625066)
134. Khambata-Ford, S. et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25, 3230-3237 (2007). (Pubitemid 47325606)
135. Garrett, J. T. & Arteaga, C. L. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol. Ther. 11, 793-800 (2011).
136. Rexer, B. N., Engelman, J. A. & Arteaga, C. L. Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 8, 18-22 (2009).
137. Montagut, C. et al. Identification of a mutation in the extracellular domain of the epidermal growth factor receptor conferring cetuximab resistance in colorectal cancer. Nature Med. 18, 221-223 (2012).
138. Scaltriti, M. et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl Cancer Inst. 99, 628-638 (2007). (Pubitemid 47073544)
139. Pao, W. et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
140. Yonesaka, K. et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci. Transl. Med. 3, 99ra86 (2011).
141. Sergina, N. V. et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437-441 (2007). (Pubitemid 46160912)
142. Berns, K. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402 (2007). (Pubitemid 47539306)
143. Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117-127 (2004). (Pubitemid 39485684)
144. Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039-1043 (2007). (Pubitemid 46799492)
145. Liu, L. et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res. 69, 6871-6878 (2009).
146. Xia, W. et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc. Natl Acad. Sci. USA 103, 7795-7800 (2006).
147. Robinson, M. K. et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br. J. Cancer 99, 1415-1425 (2008).
148. Schaefer, G. et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20, 472-486 (2011).
149. Weinstein, I. B. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297, 63-64 (2002). (Pubitemid 34743088)
150. Stelling, J. et al. Robustness of cellular functions. Cell 118, 675-685 (2004). (Pubitemid 39221728)
151. Jeong, H., Mason, S. P., Barabasi, A. L. & Oltvai, Z. N. Lethality and centrality in protein networks. Nature 411, 41-42 (2001). (Pubitemid 32428180)
152. Baselga, J. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109-119 (2012).
153. Blackwell, K. L. et al. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab- refractory metastatic breast cancer. J. Clin. Oncol. 28, 1124-1130 (2010).
154. Carpenter, G. & Cohen, S. Epidermal growth factor. Annu. Rev. Biochem. 48, 193-216 (1979). (Pubitemid 10191090)
155. Klapper, L. N. et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. Proc. Natl Acad. Sci. USA 96, 4995-5000 (1999). (Pubitemid 29214524)
156. Kitano, H. Biological robustness. Nature Rev. Genet. 5, 826-837 (2004). (Pubitemid 39457498)
157. Kholodenko, B. N., Hancock, J. F. & Kolch, W. Signalling ballet in space and time. Nature Rev. Mol. Cell Biol. 11, 414-426 (2010).
158. Lee-Hoeflich, S. T. et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68, 5878-5887 (2008).
159. Junttila, T. T. et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15, 429-440 (2009).
160. Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 6, 443-446 (2000). (Pubitemid 30208162)
161. Pettersen, E. F. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612 (2004).
162. Schulze, W. X., Deng, L. & Mann, M. Phosphotyrosine interactome of the ErbB-receptor kinase family. Mol. Syst. Biol. 1, 2005.0008 (2005).
163. Barker, A. J. et al. Studies leading to the identification of ZD1839 (Iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11, 1911-1914 (2001). (Pubitemid 32675316)
164. Masui, H. et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 44, 1002-1007 (1984). (Pubitemid 14152782)
165. Niculescu-Duvaz, I. Trastuzumab emtansine, an antibody-drug conjugate for
166. Baselga, J. et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379, 633-640 (2012).
167. Modi, S. et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17, 5132-5139 (2011).
168. Li, N., Nguyen, H. H., Byrom, M. & Ellington, A. D. Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS ONE 6, e20299 (2011).
169. Lindzen, M. et al. A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis. Oncogene 21 Nov 2011 (doi:10.1038/onc. 2011.518).
170. Lindzen, M., Lavi, S., Leitner, O. & Yarden, Y. Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands. Proc. Natl Acad. Sci. USA 107, 12559-12563 (2010).
171. Cohen, S. Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J. Biol. Chem. 237, 1555-1562 (1962).
172. Todaro, G. J., Fryling, C. & De Larco, J. E. Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc. Natl Acad. Sci. USA 77, 5258-5262 (1980). (Pubitemid 11195545)
173. Reynolds, F. H. Jr, Todaro, G. J., Fryling, C. & Stephenson, J. R. Human transforming growth factors induce tyrosine phosphorylation of EGF receptors. Nature 292, 259-262 (1981). (Pubitemid 11001846)
174. Libermann, T. A. et al. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res. 44, 753-760 (1984). (Pubitemid 14184614)
175. Semba, K., Kamata, N., Toyoshima, K. & Yamamoto, T. A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc. Natl Acad. Sci. USA 82, 6497-6501 (1985). (Pubitemid 16230541)
176. King, C. R., Kraus, M. H. & Aaronson, S. A. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229, 974-976 (1985). (Pubitemid 16248488)
177. Wada, T., Qian, X. L. & Greene, M. I. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell 61, 1339-1347 (1990).
178. Peles, E. et al. Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 69, 205-216 (1992).
179. Meyer, D. & Birchmeier, C. Multiple essential functions of neuregulin in development. Nature 378, 386-390 (1995).
180. Pollack, V. A. et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291, 739-748 (1999). (Pubitemid 29503548)
181. Kobayashi, S. et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005). (Pubitemid 40271173)
182. Lievre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995 (2006).